Literature DB >> 12667025

Gene vaccines.

Indresh K Srivastava, Margaret A Liu.   

Abstract

Gene vaccines are a new approach to immunization and immunotherapy in which, rather than a live or inactivated organism (or a subunit thereof), one or more genes that encode proteins of the pathogen are delivered. The goal of this approach is to generate immunity against diseases for which traditional vaccines and treatments have not worked, to improve vaccines, and to treat chronic diseases. Gene vaccines make use of advances in immunology and molecular biology to more specifically tailor immune responses (cellular or humoral, or both) against selected antigens. They are still under development in research and clinical trials. The mechanisms for inducing cellular (as opposed to humoral) responses against a particular antigen have been elucidated. Gene vaccines provide a means to generate specific cellular responses while still generating antibodies, if desired. In addition, by delivering only the genes that encode the particular proteins against which a protective or therapeutic immune response is desired, the potential limitations and risks of certain other approaches can be avoided. This article describes the rationale for, immunologic mechanisms involved in, and design of gene vaccines under development. Preclinical and clinical studies of these vaccines are discussed for various clinical applications, focusing on infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667025     DOI: 10.7326/0003-4819-138-7-200304010-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

1.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

2.  Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults.

Authors:  Samer S El-Kamary; Melissa Billington; Stephen Deitz; Elaina Colby; Howard Rhinehart; Yukun Wu; William Blackwelder; Robert Edelman; Albert Lee; Alan King
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

3.  Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer.

Authors:  C Trollet; Y Pereira; A Burgain; E Litzler; M Mezrahi; J Seguin; M Manich; M R Popoff; D Scherman; P Bigey
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

4.  Quantitative evaluation of DNA dissociation from liposome carriers and DNA escape from endosomes during lipid-mediated gene delivery.

Authors:  Salomé Magalhães; Sofia Duarte; Gabriel A Monteiro; Fábio Fernandes
Journal:  Hum Gene Ther Methods       Date:  2014-10       Impact factor: 2.396

5.  Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine.

Authors:  Shamaila Ashraf; Wei Kong; Shifeng Wang; Jiseon Yang; Roy Curtiss
Journal:  Vaccine       Date:  2011-04-03       Impact factor: 3.641

6.  Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity.

Authors:  Bo Sun; Zhao-Shen Li; Zhen-Xing Tu; Guo-Ming Xu; Yi-Qi Du
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

7.  Baculovirus vectors elicit antigen-specific immune responses in mice.

Authors:  Andrea Facciabene; Luigi Aurisicchio; Nicola La Monica
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 8.  Proposed mechanisms of action for prostate cancer vaccines.

Authors:  Sean M Geary; Caitlin D Lemke; David M Lubaroff; Aliasger K Salem
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

9.  Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7.

Authors:  Víctor A García-Angulo; Anjana Kalita; Mridul Kalita; Luis Lozano; Alfredo G Torres
Journal:  Infect Immun       Date:  2014-03-04       Impact factor: 3.441

10.  Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection.

Authors:  A Thermet; M Robaczewska; C Rollier; O Hantz; C Trepo; G Deleage; L Cova
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.